
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic Inc. is displaying a positive outlook due to the encouraging results from its Phase 2 trials for lead candidate vidofludimus calcium, specifically in the treatment of progressive and relapsing multiple sclerosis (MS). Results from the CALLIPER trial indicate reductions in confirmed disability worsening, along with improvements in MRI markers related to disease progression, further supported by long-term efficacy and safety data from the EMPhASIS trial. The company's strategic focus on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases is bolstered by a robust pipeline, positioning it well for advancement in pivotal trials expected by the end of 2026.
Bears say
Immunic Inc's financial outlook is hindered by significant cash burn, with quarterly research and development expenses reaching $20 million alongside general and administrative costs of $6 million, raising concerns about sustainable funding for ongoing operations. Additionally, the company’s continued reliance on capital raises, evidenced by a recent $70 million in offerings, introduces risks of further dilution that could negatively impact shareholder value. Lastly, the potential failure of its developmental candidates to meet projected peak revenue targets poses a substantial risk to the investment thesis, compounded by uncertainties around market penetration and pricing strategies.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares